DOUGLAS BILL ADVANCING IBOGAINE RESEARCH FRAMEWORK HEADS TO THE HOUSE
FRANKFORT, Ky. (March 16, 2026) — Legislation sponsored by Sen. Donald Douglas, R-Nicholasville, creating a research framework for ibogaine-based treatments has passed the Kentucky Senate and now heads to the House of Representatives for consideration.
Senate Bill 77 establishes a structured framework allowing Kentucky to explore the scientific and clinical potential of ibogaine in the treatment of opioid use disorder, co-occurring substance use disorders, and later post-traumatic stress disorder, traumatic brain injury, and other neurological or mental health conditions where early research has shown promise.
“As a physician, I have seen firsthand how devastating addiction can be for patients and their families. Any loss of life is a tragedy, especially those that we have the potential to prevent,” Douglas said. “This legislation creates a responsible pathway for Kentucky to explore medical research and the approval of life-saving medications while maintaining strong safeguards and transparency.”
SB 77 outlines a framework for the commonwealth to partner with qualified drug developers seeking to conduct FDA-approved clinical trials involving ibogaine. The legislation establishes clear standards for participation, including requirements related to clinical trial design, patient safety protocols, regulatory compliance and transparency.
The bill also includes provisions to ensure the state maintains appropriate oversight of any research partnerships and protects the public interest as new treatment options are explored and expanded.
Douglas said the legislation is designed to position Kentucky as a leader in responsible medical research while expanding the conversation around innovative approaches to improve dependence, addiction and mental health treatment.
“Kentucky continues to confront the devastating effects of addiction,” Douglas said. “This bill creates a thoughtful framework for research so we can better understand potential treatments and pursue solutions grounded in science, safety, clinical results and accountability. We hope to pave the road back to strong and happy families and a healthier, more productive workforce.”
Senate Bill 77 now moves to the House of Representatives for further consideration. Douglas said the measure could prove to be one of the most consequential pieces of legislation considered during this year’s session.